Rheumatoid Arthritis

The efficacy and safety of sarilu­mab, a human monoclonal antibody blocking the interleukin-6 receptor alpha, were evaluated for treatment of rheumatoid arthritis (RA) in 3 clinical trials, including the MOBILITY trial.

This analysis of the MOBILITY and TARGET studies showed that patients treated with sarilumab achieved responses as early as week 4, and that ongoing sarilumab treatment resulted in achievement of remission or LDA through week 24, with additional increases seen through week 52 (MOBILITY).

Tofacitinib, an oral Janus kinase inhibitor, is approved for the treatment of rheumatoid arthritis (RA).

The current study reported on updated integrated safety data from 8 randomized trials that further described the safety profile for up to 5.5 years of baricitinib in adult patients with moderately to severely active RA.

Leslie R. Harrold, MD, Associate Professor, Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, and colleagues sought to determine how rituximab affects outcomes self-reported by patients by analyzing data from a cohort of 667 patients with RA who were enrolled in the US Corrona RA Registry.

In this study, the investigators analyzed baseline data from 176 patients with RA enrolled in the Evaluation of Subclinical Cardiovascular Disease and Predictors of Events in RA cohort study from October 2004 to May 2006.

A recently published report has shown that individually tailored behavioral interventions comprised of motivational counseling and text message reminders may effectively reduce daily sedentary time in patients with rheumatoid arthritis.

Dr Verstappen and colleagues had previously shown that patients treated within 6 months of symptom onset had improved 10-year outcomes compared with those who were treated later.

The efficacy of tocilizumab in combination with methotrexate and as monotherapy was maintained for 2 years in patients with early rheumatoid arthritis (RA), according to an analysis of the results of the FUNCTION trial (Burmester G, et al. Ann Rheum Dis. 2017. Epub ahead of print). No new safety signals associated with tocilizumab were reported with longer- term follow-up of this trial.
Washington, DC—In recent decades, the increased use of biologic agents has changed the way patients with rheumatoid arthritis are treated. At the 2016 Annual Meeting of the American College of Rheumatology, James R. O’Dell, MD, Bruce Professor and Vice Chair, Internal Medicine, and Chief Division of Rheumatology, University of Nebraska Medical Center, Omaha, discussed the impact these advances have on the management of rheumatoid arthritis.
Page 3 of 9
Results 21 - 30 of 87
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology